Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination With Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants With Previously Treated Advanced Melanoma (TEBE-AM)
Sponsor: Immunocore Ltd
Listed as NCT05549297, this PHASE3 trial focuses on Advanced Melanoma and remains actively recruiting participants. Sponsored by Immunocore Ltd, it has been updated 13 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — May 2025 [monthly]
Recruiting PHASE3
Phase: PHASE2/PHASE3 → PHASE3
▶ Show 8 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2023 — Mar 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2023 — Oct 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Immunocore Ltd
For direct contact, visit the study record on ClinicalTrials.gov .